Wells Fargo raised the firm’s price target on Tenet Healthcare (THC) to $252 from $238 and keeps an Overweight rating on the shares following quarterly results. Overall, modestly higher EBITDA estimates and rolling fully to 2027 estimates offsets a material increase in the odds of enhanced exchange subsidies expiring in the firm’s price target framework, Wells says.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare Secures $1.9 Billion Credit Facility
- Tenet Healthcare Announces $2 Billion Debt Refinancing
- Tenet Healthcare price target raised to $240 from $225 at Truist
- Tenet Healthcare price target raised to $235 from $225 at Mizuho
- Tenet Healthcare price target raised to $252 from $230 at RBC Capital